Showing results (381-390 of 547) with videos related to
Sort By:
Pageof 55
Journal of the National Cancer Institute|January 2, 2017
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for TreatmentCarla Casulo, Owen O'Connor, Andrei Shustov, et al.Frontiers in Medicine|August 4, 2023
The feasibility, acceptability, and usability of telehealth visitsNaina Sinha Gregory, Alpana P Shukla, Jahi J Noel, et al.The Journal of Clinical Investigation|November 4, 2015
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphomaRebecca L Goldstein, Shao Ning Yang, Tony Taldone, et al.ACS Synthetic Biology|September 21, 2016
Rapid and Inexpensive Evaluation of Nonstandard Amino Acid Incorporation in Escherichia coliJordan W Monk, Sean P Leonard, Colin W Brown, et al.The American Journal of Pathology|January 3, 2015
α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry diseaseDinesh S Bangari, Karen M Ashe, Robert J Desnick, et al.Science (New York, N.Y.)|February 1, 2020
Engineered symbionts activate honey bee immunity and limit pathogensSean P Leonard, J Elijah Powell, Jiri Perutka, et al.British Journal of Haematology|February 7, 2019
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)Cara A Rosenbaum, Sin-Ho Jung, Brandelyn Pitcher, et al.Journal of the Neurological Sciences|October 11, 2005
Exploiting genotypic differences to identify genes important for EAE developmentScott A Jelinsky, Joy S Miyashiro, Kathryn A Saraf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategiesRebecca L Elstrom, Peter Martin, Katya Ostrow, et al.Pageof 55